Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer

Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer

<p>Supplementary Figure S6. Distribution of HER2 gene ratio in relation to PIK3CA mutation status and HER2-enriched subtype.</p>

Đã lưu trong:

Chi tiết về thư mục
Tác giả chính:	Jamunarani Veeraraghavan (16461809) (author)
Tác giả khác:	Carolina Gutierrez (14958125) (author), Carmine De Angelis (16461812) (author), Robert Davis (16461815) (author), Tao Wang (14952136) (author), Tomas Pascual (16461818) (author), Pier Selenica (15052857) (author), Katherine Sanchez (16461821) (author), Hiroaki Nitta (16461824) (author), Monesh Kapadia (16461827) (author), Anne C. Pavlick (16461830) (author), Patricia Galvan (16461833) (author), Brent Rexer (16461836) (author), Andres Forero-Torres (15053759) (author), Rita Nanda (15034401) (author), Anna M. Storniolo (16461839) (author), Ian E. Krop (15029231) (author), Matthew P. Goetz (8863130) (author), Julie R. Nangia (15123189) (author), Antonio C. Wolff (15017274) (author), Britta Weigelt (15051465) (author), Jorge S. Reis-Filho (15052878) (author), Susan G. Hilsenbeck (14952139) (author), Aleix Prat (14950504) (author), C. Kent Osborne (15055636) (author), Rachel Schiff (14958948) (author), Mothaffar F. Rimawi (15055651) (author)
Được phát hành:	2025
Những chủ đề:	Cancer Cancer Detection and Diagnosis Biomarkers Prognostic biomarkers Breast Cancer
Các nhãn:	Thêm thẻ Không có thẻ, Là người đầu tiên thẻ bản ghi này!

Những quyển sách tương tự

Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Bằng: Jamunarani Veeraraghavan (16461809)
Được phát hành: (2025)

Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Bằng: Jamunarani Veeraraghavan (16461809)
Được phát hành: (2025)

Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Bằng: Jamunarani Veeraraghavan (16461809)
Được phát hành: (2025)

Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Bằng: Jamunarani Veeraraghavan (16461809)
Được phát hành: (2025)

Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Bằng: Jamunarani Veeraraghavan (16461809)
Được phát hành: (2025)

Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Bằng: Jamunarani Veeraraghavan (16461809)
Được phát hành: (2025)

Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Bằng: Nigel Bundred (15046233)
Được phát hành: (2025)

Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Bằng: Nigel Bundred (15046233)
Được phát hành: (2025)

Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Bằng: Nigel Bundred (15046233)
Được phát hành: (2025)

Table 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Bằng: Nigel Bundred (15046233)
Được phát hành: (2025)

Table 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
Bằng: Nigel Bundred (15046233)
Được phát hành: (2025)

Supplementary Table S1 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Bằng: Emil Christensen (15054394)
Được phát hành: (2025)

Supplementary Table S2 from Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
Bằng: Emil Christensen (15054394)
Được phát hành: (2025)

Supplementary Tables S1-5 from METTL3-Mediated m<sup>6</sup>A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Bằng: Yiming Wu (15306005)
Được phát hành: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Bằng: Hansol Lee (15054787)
Được phát hành: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Bằng: Hansol Lee (15054787)
Được phát hành: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Bằng: Hansol Lee (15054787)
Được phát hành: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
Bằng: Hansol Lee (15054787)
Được phát hành: (2025)

Supplementary Video S1 from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Bằng: Xiaojiang Duan (15439264)
Được phát hành: (2025)

Supplementary Video S2A from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Bằng: Xiaojiang Duan (15439264)
Được phát hành: (2025)

Supplementary Video S2B from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Bằng: Xiaojiang Duan (15439264)
Được phát hành: (2025)

Supplementary Video S2C from First-in-Human Study of the Radioligand <sup>68</sup>Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma
Bằng: Xiaojiang Duan (15439264)
Được phát hành: (2025)

Figure 1 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Bằng: Milana A. Bergamino (15038015)
Được phát hành: (2025)

Figure 2 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Bằng: Milana A. Bergamino (15038015)
Được phát hành: (2025)

Figure 3 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Bằng: Milana A. Bergamino (15038015)
Được phát hành: (2025)

Figure 4 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Bằng: Milana A. Bergamino (15038015)
Được phát hành: (2025)

Figure 5 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Bằng: Milana A. Bergamino (15038015)
Được phát hành: (2025)

Figure 6 from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Bằng: Milana A. Bergamino (15038015)
Được phát hành: (2025)

Supplementary Data from Genetic Modulation of <i>BET1L</i> Confers Colorectal Cancer Susceptibility by Reducing miRNA Binding and m<sup>6</sup>A Modification
Bằng: Shuwei Li (16437116)
Được phát hành: (2025)

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
Bằng: Hiroshi Kagamu (14961732)
Được phát hành: (2025)

Supplementary Appendix S1 from DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
Bằng: Bouchra Tawk (15389486)
Được phát hành: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
Bằng: Ankita Mitra (17141783)
Được phát hành: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
Bằng: Ankita Mitra (17141783)
Được phát hành: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
Bằng: Ankita Mitra (17141783)
Được phát hành: (2025)

UMAP visualizations of extracted CD8<sup> + </sup> T and CD4<sup> + </sup> T cell barcodes, employed for downstream subsequent single-cell trajectory and classification analyses.
Bằng: Fatemeh Keikha (20917848)
Được phát hành: (2025)

Supplementary Figure S1 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Bằng: Carlotta Antoniotti (15352506)
Được phát hành: (2025)

Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Bằng: Carlotta Antoniotti (15352506)
Được phát hành: (2025)

Supplementary Figure S3 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer
Bằng: Carlotta Antoniotti (15352506)
Được phát hành: (2025)

Supplementary Figure S1 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Bằng: Javier Pascual (15018176)
Được phát hành: (2025)

Supplementary Figure S2 from Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
Bằng: Javier Pascual (15018176)
Được phát hành: (2025)

Cannot write session to /tmp/vufind_sessions/sess_n4au7hbgrmjq0b19ru5ekg5a8f